New Zealand markets closed

Biotech and Drug Stocks

Biotech and Drug Stocks

4.43k followers31 symbols Watchlist by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies.

Curated by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.

The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.

This watchlist is similar to a discontinued watchlist called Battling Cancer.


Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.


WatchlistChange today1-month return1-year returnTotal return
Biotech and Drug Stocks+1.13%---

31 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson171.79+1.81+1.06%4:00 pm GMT-45.02M6.69M452.39B
RHHBYRoche Holding AG47.03+0.61+1.31%3:59 pm GMT-4885.93k1.29M329.23B
LLYEli Lilly and Company244.15+5.66+2.37%4:02 pm GMT-42.45M3.43M234.15B
PFEPfizer Inc.41.68+0.21+0.51%4:02 pm GMT-417.94M25.01M233.31B
NVONovo Nordisk A/S90.75+2.53+2.87%4:00 pm GMT-41.65M908.67k209.57B
ABBVAbbVie Inc.118.19+0.65+0.55%4:02 pm GMT-44.34M6.37M208.75B
NVSNovartis AG91.57+0.49+0.54%4:00 pm GMT-41.64M1.81M205.78B
MRKMerck & Co., Inc.77.54+1.01+1.32%4:02 pm GMT-46.56M12.12M196.34B
AZNAstraZeneca PLC58.23+0.27+0.47%4:00 pm GMT-414.13M10.43M180.92B
BMYBristol-Myers Squibb Company68.34+0.38+0.56%4:00 pm GMT-47.09M9.64M152.59B
AMGNAmgen Inc.247.72+2.98+1.22%4:00 pm GMT-41.59M2.61M142.33B
MRNAModerna, Inc.348.83+25.35+7.84%4:00 pm GMT-423.39M12.55M140.07B
SNYSanofi51.86+0.44+0.86%4:00 pm GMT-42.02M1.36M129.91B
GSKGlaxoSmithKline plc39.51+0.28+0.71%4:00 pm GMT-43.76M4.25M99.40B
ZTSZoetis Inc.203.59+3.05+1.52%4:03 pm GMT-4932.25k1.78M96.66B
GILDGilead Sciences, Inc.69.02+0.37+0.54%4:00 pm GMT-43.40M6.84M86.56B
BNTXBioNTech SE281.96+0.98+0.35%4:00 pm GMT-44.46M3.12M68.10B
REGNRegeneron Pharmaceuticals, Inc.586.35-0.53-0.09%4:00 pm GMT-4628.25k758.83k62.47B
BAYRYBayer Aktiengesellschaft14.97-0.03-0.20%3:59 pm GMT-4578.23k385.49k59.22B
TAKTakeda Pharmaceutical Company Limited16.86+0.05+0.30%4:00 pm GMT-4914.04k2.02M53.16B
VRTXVertex Pharmaceuticals Incorporated200.5+4.48+2.29%4:00 pm GMT-42.89M2.20M51.90B
BIIBBiogen Inc.325.4-0.96-0.29%4:00 pm GMT-41.02M2.01M48.99B
ALXNAlexion Pharmaceuticals, Inc.182.5--4:00 pm GMT-43.004.06M40.34B
GMABGenmab A/S44.85+0.49+1.10%4:00 pm GMT-4218.87k501.58k29.38B
SGENSeagen Inc.145.6+2.27+1.58%4:00 pm GMT-4803.34k805.72k26.42B
RPRXRoyalty Pharma plc40.33-0.03-0.07%4:00 pm GMT-41.00M1.94M24.49B
HZNPHorizon Therapeutics Public Limited Company101.05+0.98+0.98%4:00 pm GMT-41.61M1.55M22.71B
ALNYAlnylam Pharmaceuticals, Inc.182.41+0.60+0.33%4:00 pm GMT-4512.28k635.49k21.44B
CTLTCatalent, Inc.116.26+1.07+0.93%4:02 pm GMT-4558.51k912.30k19.80B
TECHBio-Techne Corporation474.4+5.22+1.11%4:00 pm GMT-4116.92k252.81k18.45B
  • Motley Fool

    Why Is Novo Nordisk Buying a Rare-Disease Candidate?

    Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

  • 3 Biotech Stocks That Could Rocket Higher
    Motley Fool

    3 Biotech Stocks That Could Rocket Higher

    Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

  • 3 Value Stocks to Buy for the Second Half of 2021
    Motley Fool

    3 Value Stocks to Buy for the Second Half of 2021

    Here are three value stocks to buy for the second half of 2021. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. The company's revenue grew 51% year over year in the first quarter of 2021.